BIOMARIN PHARMACEUTICAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $BMRN in the last 7 days.
No SEC Form 4 filings for $BMRN in the last 30 days.
See all $BMRN insider activity →Cantor Fitzgerald maintained an Overweight rating on BioMarin Pharmaceutical (BMRN) with an $86 price target, suggesting a 57.3% upside from the Oct 19 close of $54.67. The firm cited BioMarin's strong pipeline and established market presence in rare genetic diseases.
BioMarin Pharmaceutical (BMRN) shares rose following a Buy rating from UBS, which cited undervaluation relative to 2027 earnings. The FDA submission for Voxzogo's label expansion and positive clinical data also boosted investor confidence. The company's revenue growth and higher guidance indicate traction in rare-disease drugs, but margin pressure and acquisition financing costs remain concerns.
UBS analyst Joon Lee lowered BioMarin Pharmaceutical's (BMRN) price target to $88.00 from $114.00, a 22.81% reduction, while maintaining a 'Buy' rating. The stock is trading at $56.05, which is 36.5% undervalued compared to its GF Value™ of $88.30. BioMarin has a GF Score™ of 73/100, indicating solid performance relative to peers, but shows mixed insider and institutional activity.
Recent BMRN coverage spans financial news, earnings and market movers.
Analyst upgrade and higher price target suggest positive sentiment and potential buying pressure.
The upgrade and label expansion suggest near‑term upside.
Target reduction suggests lower valuation expectations.
Analyst upgrade to Strong Buy suggests upside potential.
Positive rating and higher target may drive buying pressure.
AlphAI scores every news story that mentions BMRN with an AI model for sentiment and relevance, and aggregates insider trades from BIOMARIN PHARMACEUTICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cantor Fitzgerald maintained an Overweight rating on BioMarin Pharmaceutical (BMRN) with an $86 price target, suggesting a 57.3% upside from the Oct 19 close of $54.67. The firm cited BioMarin's strong pipeline and established market presence in rare genetic diseases.
1 min readBioMarin Pharmaceutical (BMRN) shares rose following a Buy rating from UBS, which cited undervaluation relative to 2027 earnings. The FDA submission for Voxzogo's label expansion and positive clinical data also boosted investor confidence. The company's revenue growth and higher guidance indicate traction in rare-disease drugs, but margin pressure and acquisition financing costs remain concerns.
2 min readUBS analyst Joon Lee lowered BioMarin Pharmaceutical's (BMRN) price target to $88.00 from $114.00, a 22.81% reduction, while maintaining a 'Buy' rating. The stock is trading at $56.05, which is 36.5% undervalued compared to its GF Value™ of $88.30. BioMarin has a GF Score™ of 73/100, indicating solid performance relative to peers, but shows mixed insider and institutional activity.
2 min readRaymond James upgraded BioMarin (BMRN) to Strong Buy with a $109 price target, citing undervaluation and strong growth prospects. The stock trades at $54.80, down 7.8% YTD. Other analysts have mixed views, with price targets ranging from $60 to $97. BioMarin also discontinued Voxzogo development for Noonan syndrome.
2 min readBank of America Securities analyst Jason Gerberry maintained a Buy rating on BioMarin Pharmaceutical (BMRN) with a $86.00 price target. BMO Capital also gave a Buy rating, while RBC Capital maintained a Hold. BioMarin reported Q2 revenue of $989.71M and net profit of $44.76M, down from last year's $825.41M revenue and $240.53M profit. Insider sentiment is negative, with recent sales by executives.
1 min readBioMarin Pharmaceutical and Zydus Lifesciences settled a patent dispute over Zydus' proposed copies of BioMarin's dwarfism drug Voxzogo. The agreement blocks Zydus from infringing eight patents unless otherwise agreed. Voxzogo generated $926.9 million in 2025, 28.77% of BioMarin's revenue.
2 min readBioMarin Pharmaceutical Inc. (BMRN) presented new data at the American Society for Bone and Mineral Research 2026 Annual Meeting, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia. The data showed encouraging imaging results from a trial evaluating VOXZOGO's effect on the growth of the foramen magnum and craniocervical junction in children with achondroplasia.
2 min readBioMarin Pharmaceutical (BMRN) reported a $283M Q3 IPR&D expense, reducing GAAP and non-GAAP EPS by $1.50. Non-GAAP EPS is estimated at $1.25. The expense impacts financial results for the quarter.
1 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition Estimated Financial Impact of the Alesta Acquisition In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid),
2 min readBioMarin (BMRN) presented five-year data for POMBILITI + OPFOLDA in late-onset Pompe disease at the World Muscle Society Congress. The study showed durable motor function and pulmonary stabilization. No new safety signals were identified. Additionally, BioMarin shared positive Phase 1/2 data for nivudirsen (BMN 351) in Duchenne muscular dystrophy, showing favorable tolerability and positive dystrophin expression.
2 min read
